Lipoarabinomannan (LAM) is a unique cell wall component containing a fatty acid region with a large mannan core attached to poly-arabinan chains, sometimes followed by mannose capping in Actinomyces species. The hydrophobic region made of tuberculostearic acid (TBSA) and two palmitic acid chains linked to a phosphoinositol, anchors LAM to the mycobacterial cell wall. As a major constituent of all mycobacteria, includingMycobacterium tuberculosis(M.tb),LAM has been shown to be a useful diagnostic biomarker in the identification of MTB infection in HIV positive (HIV+) patients. The size of LAM makes it difficult to analyze on GC-MS when using complex matrices such as urine, therefore chemical processing and derivatization is required. Two methods have been developed to quantify urine-LAM amounts, one by measuring D-arabinose and the other TBSA. Both components are unique and not metabolized through basic pathways in mammalian cells and can therefore serve as LAM surrogates. Using either chemical assay, urine-LAM can be detected in low quantities with sensitive GC-MS, providing a diagnostic tool for clinical assessment of infection. These methods are robust and have been applied to a significant number of TB and non-tuberculous mycobacterial (NTM) urine samples. These protocols provide additional sensitivity beyond what is required for assays of MTB in HIV+ patients, allowing for identification of both M.tb and NTM infections in immunocompetent hosts.
No takes yet. Share an insight, caveat, or question.
Manzer et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: